EXHIBIT 99.1 Aptose Reports Second Quarter 2025 Results SAN DIEGO and TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. Report maturing data from TUS+ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

PART I—FINANCIAL INFORMATION [Financial Statements](index=4&type=section&id=Item%201%20%E2%80%93%20Financial%20Statements) This section presents unaudited condensed consolidated interim financial statements, highlighting a 'going concern' warning due to cash projected to fund operations only through May 2025 - The company's ability to continue as a going concern is in substantial doubt, as its cash and cash equivalents as of March 31, 2025, are projected to support operations only through **May 2025**[24](index=24&type=chunk)[26](index=26&type=chunk)[30](index=30&type=chunk) Condensed Consolidated Statements of Financial Position (Unaudited) | (In thousands of US dollars) | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $4,743 | $6,152 | | Total current assets | $6,969 | $9,530 | | Total assets | $7,467 | $10,127 | | **Liabilities and Shareholders' Deficit** | | | | Total current liabilities | $6,318 | $4,477 | | Total liabilities | $14,860 | $14,670 | | Total shareholders' deficit | $(7,393) | $(4,543) | Condensed Consolidated Statements of Loss and Comprehensive Loss (Unaudited) | (In thousands of US dollars, except per share data) | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Revenue | $— | $— | | Research and development | $2,364 | $6,445 | | General and administrative | $3,097 | $3,315 | | Net loss | $(5,543) | $(9,640) | | Basic and diluted loss per common share | $(2.61) | $(22.02) | Condensed Consolidated Statements of Cash Flows (Unaudited) | (In thousands of US dollars) | Three months ended March 31, 2025 | Three months ended March 31, 2024 | | :--- | :--- | :--- | | Cash used in operating activities | $(2,795) | $(11,763) | | Cash used in investing activities | $— | $(1,991) | | Cash provided by financing activities | $829 | $11,847 | | Decrease in cash, cash equivalents and restricted cash | $(1,964) | $(1,906) | - On February 26, 2025, the company executed a **1-for-30 reverse stock split** of its Common Shares. All share and per-share amounts have been retroactively adjusted[24](index=24&type=chunk) - On March 18, 2025, the company entered into a Debt Conversion Agreement with Hanmi Pharmaceutical, converting **$1.5 million of debt** into **409,063 Common Shares** at **$3.70 per share**[50](index=50&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202%20%E2%80%93%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management analyzes the company's financial condition and operational results, focusing on clinical programs, liquidity, and capital resources, amidst significant 'going concern' risk [Overview and Program Updates](index=20&type=section&id=Overview%20and%20Program%20Updates) Aptose, a clinical-stage biotech, focuses on hematology with its lead program, tuspetinib, showing promising early data in AML, while luxeptinib development is paused - The lead program, tuspetinib, is being developed as a frontline triplet combination therapy (TUS+VEN+HMA) for newly diagnosed AML patients, aiming to establish a new standard of care[93](index=93&type=chunk)[94](index=94&type=chunk)[95](index=95&type=chunk) - The TUSCANY Phase 1/2 trial of the TUS+VEN+AZA triplet has shown early positive results, achieving complete remissions in difficult-to-treat AML patients at the initial **40 mg dose** of tuspetinib, leading to dose escalation to **80 mg**[95](index=95&type=chunk)[107](index=107&type=chunk)[108](index=108&type=chunk) - Development of the luxeptinib program has been paused to conserve funds and prioritize the advancement of tuspetinib[100](index=100&type=chunk)[132](index=132&type=chunk) - Aptose entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to collaborate on the clinical development of tuspetinib in NCI-sponsored myeloMATCH trials[104](index=104&type=chunk) [Results of Operations](index=33&type=section&id=Results%20of%20Operations) The company reported a net loss of **$5,543 thousand** for Q1 2025, a significant decrease from Q1 2024, primarily due to reduced Research and Development expenses Comparison of Operating Results (Q1 2025 vs Q1 2024) | (In thousands of US dollars) | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Net Loss | $5,543 | $9,640 | $(4,097) | | Research & Development Expenses | $2,364 | $6,445 | $(4,081) | | General & Administrative Expenses | $3,097 | $3,315 | $(218) | - R&D expenses decreased by **$4,081 thousand** year-over-year, mainly due to reduced activity in the tuspetinib APTIVATE clinical trial, lower manufacturing costs, and a reduction in R&D personnel headcount[179](index=179&type=chunk)[183](index=183&type=chunk) - G&A expenses decreased by **$218 thousand**, primarily due to a **$300 thousand** reduction in stock-based compensation expense, partially offset by a **$100 thousand** increase in legal and consulting fees[182](index=182&type=chunk)[184](index=184&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company's financial position is precarious, with cash reserves projected to last only through May 2025, raising substantial doubt about its ability to continue as a going concern - The company has sufficient liquidity to support operations only through **May 2025**, which raises substantial doubt about its ability to continue as a going concern[142](index=142&type=chunk)[148](index=148&type=chunk)[150](index=150&type=chunk) Key Liquidity Metrics | (In thousands of US dollars) | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $4,743 | $6,152 | | Working capital | $651 | $5,053 | | Stockholders' deficit | $(7,393) | $(4,543) | - The company was delisted from the Nasdaq Stock Market effective **April 2, 2025**, for failing to regain compliance with the minimum stockholders' equity requirement. Its shares continue to trade on the TSX and OTC markets[88](index=88&type=chunk)[141](index=141&type=chunk) - In Q1 2025, the company raised net proceeds of **$829 thousand** through its 2025 At-The-Market (ATM) facility by issuing **137,000 common shares**[152](index=152&type=chunk)[174](index=174&type=chunk) [Qualitative and Quantitative Disclosures about Market Risk](index=36&type=section&id=Item%203%20%E2%80%93%20Qualitative%20and%20Quantitative%20Disclosures%20about%20Market%20Risk) As a 'smaller reporting company' under SEC rules, the company is not required to provide disclosures about market risk - Aptose Biosciences is not required to provide information on market risk because it qualifies as a 'smaller reporting company' under SEC regulations[191](index=191&type=chunk) [Controls and Procedures](index=36&type=section&id=Item%204%20%E2%80%93%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were ineffective as of March 31, 2025, due to a material weakness in internal control over financial reporting, with a remediation plan underway - Management concluded that disclosure controls and procedures were not effective as of **March 31, 2025**[192](index=192&type=chunk) - The ineffectiveness is due to a material weakness in internal control over financial reporting related to the accounting for complex financial instruments, specifically warrants[192](index=192&type=chunk) - A remediation plan is underway to address the material weakness, involving engaging specialists for technical accounting analysis and providing additional training to employees[195](index=195&type=chunk) PART II—OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201%20%E2%80%93%20Legal%20Proceedings) The company is not currently involved in any material active legal proceedings, though it may be subject to ordinary course legal actions - As of the filing date, the company is not involved in any material active legal actions[198](index=198&type=chunk) [Risk Factors](index=37&type=section&id=Item%201A%20%E2%80%93%20Risk%20Factors) This section supplements annual 10-K risk factors, emphasizing the immediate 'Going Concern Risk' due to limited cash runway, imminent bankruptcy risk, and urgent funding needs - The company's financial statements have been prepared on a going concern basis, but its ability to continue is in substantial doubt as current cash is only projected to support operations through **May 2025**[199](index=199&type=chunk) - As of the filing date, the company's cash-on-hand was approximately **$2.2 million**, and it had a working capital deficiency[201](index=201&type=chunk) - Newly highlighted risks include the risk of imminent bankruptcy, the need to obtain substantial funding immediately, and potential work stoppages or contract changes from key suppliers[200](index=200&type=chunk) - A single contract research organization represented **43%** of the company's accounts payable as of **March 31, 2025**[200](index=200&type=chunk) [Exhibits](index=39&type=section&id=Item%206%20%E2%80%93%20Exhibits) This section lists exhibits filed with the Form 10-Q, including certifications of Principal Executive and Financial Officers and Inline XBRL financial statements List of Filed Exhibits | Exhibit Number | Description | | :--- | :--- | | 31.1 | Certification of Principal Executive Officer (Section 302) | | 31.2 | Certification of Principal Financial Officer (Section 302) | | 32.1 | Certification of Principal Executive Officer (Section 906) | | 32.2 | Certification of Principal Financial Officer (Section 906) | | 101 | Inline XBRL Financial Statements | [Signatures](index=40&type=section&id=Signatures) The quarterly report was officially signed by William G. Rice, Ph.D., President and CEO of Aptose Biosciences Inc., on May 8, 2025 - The report was duly signed by **William G. Rice, Ph.D.**, President and Chief Executive Officer, on **May 8, 2025**[205](index=205&type=chunk)[206](index=206&type=chunk)

[Report Overview & Highlights](index=1&type=section&id=Report%20Overview%20%26%20Highlights) [TUSCANY Clinical Trial Progress](index=1&type=section&id=TUSCANY%20Clinical%20Trial%20Progress) The TUSCANY trial for frontline AML with tuspetinib, venetoclax, and azacitidine shows robust safety and response, with all six patients achieving complete remissions across escalated doses up to 80 mg, including those with adverse mutations - The TUSCANY trial is evaluating a tuspetinib (TUS)-based triple drug frontline therapy (TUS+VEN+AZA) for newly diagnosed AML patients[2](index=2&type=chunk) - The tuspetinib dose was escalated from an initial **40 mg to 80 mg** in the triplet therapy[3](index=3&type=chunk) - All **six patients** treated in the first two cohorts (three at **40 mg** and three at **80 mg**) achieved Complete Remissions (CRs) and remain on treatment[3](index=3&type=chunk) - In the **40 mg cohort**, **three of four patients** achieved CRs, and all three were reported as MRD-negative[4](index=4&type=chunk) - In the **80 mg cohort**, all **three patients** achieved CRs, with no safety concerns or dose-limiting toxicities (DLTs) reported to date[5](index=5&type=chunk) - The therapy has shown effectiveness in patients with diverse and adverse mutation profiles, including **TP53**, **FLT3-ITD**, **IDH2**, and **DDX41** mutations[3](index=3&type=chunk)[4](index=4&type=chunk)[5](index=5&type=chunk) [Corporate Updates](index=1&type=section&id=Corporate%20Updates) Aptose common shares were delisted from Nasdaq due to non-compliance and now trade on OTC Markets under "APTOF" to enhance U.S. investor accessibility and liquidity, while maintaining TSX listing - Aptose common shares now trade on the OTC Markets under the ticker "**APTOF**" in addition to the Toronto Stock Exchange (TSX) under "**APS**"[5](index=5&type=chunk) - The company's common shares were delisted from The Nasdaq Stock Market effective **April 2, 2025**, because of non-compliance with the exchange's equity requirements[5](index=5&type=chunk) - The move to OTC is part of a strategy to increase visibility and participation from the U.S. investment community and enhance overall share liquidity[5](index=5&type=chunk) [Completed and Planned Value-Creating Milestones](index=1&type=section&id=Completed%20and%20Planned%20Value-Creating%20Milestones) Aptose reported initial safety and efficacy data for TUS+VEN+AZA cohorts, with plans to present maturing data at EHA and ASH in 2025, aiming to select the optimal tuspetinib dose for pivotal Phase 2/3 trials - Reported initial safety and efficacy data for both the **40mg and 80mg TUS+VEN+AZA cohorts**[12](index=12&type=chunk) - Plan to report maturing data from the triplet study at the European Hematology Association (EHA) in **1H 2025**[7](index=7&type=chunk) - Plan to report response rate and durability data at the American Society of Hematology (ASH) in **2025**[8](index=8&type=chunk)[12](index=12&type=chunk) - Future goals include selecting the tuspetinib dose for pivotal Phase 2/3 trials and preparing for their initiation[12](index=12&type=chunk) [Financial Results of Operations](index=2&type=section&id=FINANCIAL%20RESULTS%20OF%20OPERATIONS) [Financial Summary (Statements of Operations)](index=2&type=section&id=Financial%20Summary%20(Statements%20of%20Operations)) Aptose reported a Q1 2025 net loss of **$5.5 million**, a significant improvement from **$9.6 million** in Q1 2024, driven by reduced operating expenses, with net loss per share improving to **$2.61** from **$22.02** Q1 2025 vs Q1 2024 Statement of Operations ($ in thousands) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Research and development | $2,364 | $6,445 | | General and administrative | $3,097 | $3,315 | | **Operating expenses** | **$5,461** | **$9,760** | | **Net loss** | **$(5,543)** | **$(9,640)** | | Net loss per share | $(2.61) | $(22.02) | | Weighted average shares | 2,126,287 | 437,750 | [Balance Sheet Summary](index=2&type=section&id=Balance%20Sheet%20Summary) As of March 31, 2025, Aptose reported **$4.7 million** in cash, **$7.5 million** in total assets, and a shareholders' deficit of **$7.4 million**, reflecting a decrease in cash and an increased deficit from year-end 2024 Balance Sheet Data ($ in thousands) | Metric | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents and restricted cash | $4,743 | $6,707 | | Working capital | $651 | $5,053 | | Total assets | $7,467 | $10,127 | | Long-term liabilities | $8,542 | $10,193 | | Accumulated deficit | $(546,510) | $(540,967) | | Shareholders' deficit | $(7,393) | $(4,543) | [Research and Development Expenses](index=3&type=section&id=RESEARCH%20AND%20DEVELOPMENT%20EXPENSES) Q1 2025 R&D expenses significantly decreased to **$2.4 million** from **$6.4 million** in Q1 2024, primarily due to reduced tuspetinib program costs, lower personnel expenses, and the discontinuation of the APTO-253 program R&D Expense Breakdown - Q1 2025 vs Q1 2024 ($ in thousands) | Program | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Tuspetinib | $1,479 | $3,923 | | Luxeptinib | $98 | $208 | | APTO-253 | $- | $22 | | Personnel related expenses | $646 | $1,924 | | Stock-based compensation | $141 | $328 | | **Total R&D Expenses** | **$2,364** | **$6,445** | - Tuspetinib program costs decreased by **$2.4 million** due to reduced activity in the APTIVATE clinical trial and lower manufacturing expenses[16](index=16&type=chunk) - Personnel-related expenses decreased by **$1.3 million** due to lower R&D headcount[16](index=16&type=chunk) - The APTO-253 program was discontinued, eliminating its associated costs[16](index=16&type=chunk) [Liquidity and Capital Resources](index=3&type=section&id=Liquidity%20and%20Capital%20Resources) As of March 31, 2025, Aptose held **$4.7 million** in cash, projecting funding only until May 2025, and is actively pursuing financing and cost-reduction strategies to extend its cash runway - Total cash, cash equivalents and restricted cash equivalents were **$4.7 million** as of March 31, 2025[15](index=15&type=chunk) - The company expects its current cash on hand to fund operations only until the end of **May 2025**[15](index=15&type=chunk) - Aptose is proactively implementing financing and cost reduction efforts to extend its cash runway[15](index=15&type=chunk) - As of May 1, 2025, the company had **2,552,429** common shares issued and outstanding[15](index=15&type=chunk) [Corporate Information & Disclosures](index=3&type=section&id=Corporate%20Information%20%26%20Disclosures) [About Aptose](index=3&type=section&id=About%20Aptose) Aptose Biosciences is a clinical-stage biotechnology company developing precision oncology medicines, with its lead compound, tuspetinib, an oral kinase inhibitor, targeting frontline acute myeloid leukemia - Aptose is a clinical-stage biotechnology company developing precision medicines for oncology, with a focus on hematology[15](index=15&type=chunk) - The company's lead clinical-stage compound is **tuspetinib (TUS)**, an oral kinase inhibitor for acute myeloid leukemia (AML)[17](index=17&type=chunk) [Forward-Looking Statements](index=4&type=section&id=Forward%20Looking%20Statements) This section serves as a legal disclaimer for forward-looking statements, highlighting risks like capital acquisition, drug development efficacy, and market conditions, with no obligation to update unless legally required - The press release contains forward-looking statements that are subject to significant risks, uncertainties, and assumptions[18](index=18&type=chunk) - Key risks include the ability to obtain required capital, drug development efficacy, regulatory approval processes, clinical trial progress, and changing economic conditions[18](index=18&type=chunk) - Aptose does not assume any obligation to update these forward-looking statements, except as required by law[19](index=19&type=chunk)

Summary of Aptose Biosciences Conference Call Company Overview - **Company**: Aptose Biosciences - **Focus**: Clinical stage precision oncology company developing Tuspitinib for acute myeloid leukemia (AML) treatment [2][12] Industry Context - **Disease**: Acute Myeloid Leukemia (AML) - **Characteristics**: Aggressive cancer of the bone marrow and blood, primarily affecting patients aged 65 and older [5][6] - **Current Treatment**: Standard of care is a two-drug cocktail (Venaza: Venetoclax and Azacitidine) [6][9] - **Survival Rates**: Five-year survival rate for patients aged 65+ is approximately 9% [6] Core Points and Arguments - **Need for Improved Therapy**: - Current therapies have high rates of refractoriness (one-third of patients do not respond) and limited overall survival (median of 14.7 months for responders) [7][8] - Need for therapies that are broadly active across all genetic subtypes of AML [9][12] - **Tuspitinib's Role**: - Described as a safe, mutation-agnostic third drug to be added to the Venaza backbone [12][48] - Demonstrated excellent safety profile, convenient administration (once daily oral tablets), and broad activity against various AML mutations [13][48] - Potential market opportunity exceeding $1 billion annually [14] - **Clinical Trials**: - **Tuscany Trial**: Focused on newly diagnosed AML patients, aiming to select optimal dosing for pivotal studies [19][38] - Initial dosing started at 40 mg, escalated to 80 mg, with promising results in terms of complete remissions and minimal toxicity [20][22][24] - Patients achieving complete remission (CR) and minimal residual disease (MRD) negativity, indicating potential for durable responses [26][37] - **Regulatory Status**: - Orphan drug designation and fast track status received from the FDA [18] - Required to start trials in relapsed/refractory patients before moving to newly diagnosed patients [16] Important but Overlooked Content - **Patient Case Studies**: - Multiple case studies presented showing diverse mutation profiles and successful outcomes with Tuspitinib [30][34][36] - Highlighted the drug's effectiveness in patients with challenging mutations like TP53, which are often excluded from clinical trials [29][34] - **Upcoming Milestones**: - Data presentation at the European Hematology Association meeting and the American Society of Hematology meeting planned for later in the year [40][42] - Selection of pivotal trial dose expected within the year [38][49] - **Company Structure**: - Small team of 15 full-time employees, with a strong advisory board including key opinion leaders in AML and MDS [43][45] Conclusion - Aptose Biosciences is positioned to address significant unmet needs in AML treatment with its lead drug Tuspitinib, supported by promising clinical data and a strategic focus on broad applicability across genetic subtypes. The company is on track for pivotal trials and has garnered interest from major pharmaceutical companies.

Core Insights - Aptose Biosciences is developing a unique triple drug therapy (TUS+VEN+AZA) for newly diagnosed acute myeloid leukemia (AML) patients, aiming for a safe and mutation-agnostic frontline treatment [1][6] - Initial data from the Phase 1/2 TUSCANY trial shows promising safety and efficacy, with complete remissions and measurable residual disease (MRD) negativity observed in patients with diverse mutations [1][4] Group 1: Clinical Trial Details - The TUSCANY trial has initiated dosing with tuspetinib (TUS) at 40 mg and 80 mg in combination with venetoclax (VEN) and azacitidine (AZA), demonstrating safety and antileukemic activity [2][4] - The trial is designed to evaluate various doses and schedules of TUS for AML patients who cannot receive induction chemotherapy, with a target enrollment of 18-24 patients by mid-late 2025 [7] Group 2: Patient Outcomes - In the first cohort, a patient with biallelic TP53 mutations achieved complete remission and MRD-negative status, while another FLT3-wildtype patient also achieved complete remission [4] - In the second cohort receiving 80 mg of TUS, all three patients showed blast reductions meeting criteria for complete remissions or complete remission with incomplete blood count recovery (CRi) [4] Group 3: Company Overview - Aptose Biosciences focuses on developing precision medicines for oncology, with tuspetinib as a lead candidate showing activity in relapsed or refractory AML and being advanced as a frontline therapy [9]

Core Viewpoint - Aptose Biosciences Inc. announced that KPMG LLP will not stand for re-appointment as the independent registered public accounting firm for the 2025 annual audit, while KPMG will continue to review the company's quarterly interim financial results through the first two fiscal quarters of 2025 [1]. Group 1: Company Announcement - KPMG did not seek the company's consent regarding its decision not to stand for re-appointment, and neither the Board of Directors nor the Audit Committee participated in this decision [2]. - KPMG issued unqualified reports on the company's consolidated financial statements for the fiscal years ended December 31, 2024, and 2023 [3]. - There were no disagreements or reportable events between the company and KPMG during the fiscal years ended December 31, 2024, and 2023, except for a communicated material weakness in internal control over financial reporting related to complex financial instruments [4]. Group 2: Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [6]. - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor being developed as a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML) [6].

Core Viewpoint - Aptose Biosciences Inc. is participating in the 2025 Bloom Burton & Co. Healthcare Investor Conference to present its developments in precision oncology, specifically focusing on its lead compound tuspetinib for treating acute myeloid leukemia [1][4]. Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, with an emphasis on hematology [5]. - The company's lead product, tuspetinib (TUS), is an oral kinase inhibitor that has shown efficacy as both a monotherapy and in combination therapy for relapsed or refractory acute myeloid leukemia (AML) [5]. - Tuspetinib is being developed as a frontline triplet therapy for newly diagnosed AML patients [5]. Conference Details - The 2025 Bloom Burton & Co. Healthcare Investor Conference will take place on May 5-6, 2025, in Toronto [1][4]. - Dr. William G. Rice, Chairman, President, and CEO of Aptose, will present on May 5, 2025, at 3:00 p.m. EDT [2][3]. - The presentation will be available via webcast, and further details can be found on the Aptose website [3]. Investor Engagement - The conference provides an opportunity for investors to receive corporate updates from various Canadian healthcare companies through presentations and one-on-one meetings [4]. - Aptose is open to scheduling one-on-one meetings with interested investors during the conference [2].

Core Insights - Aptose Biosciences Inc. is a clinical-stage precision oncology company focused on developing tuspetinib (TUS) as a frontline therapy for newly diagnosed acute myeloid leukemia (AML) [1][5] - The company will participate in the 2025 Bloom Burton & Co. Healthcare Investor Conference in Toronto on May 5-6, 2025, where Dr. William G. Rice will present and host one-on-one meetings [1][2][4] Company Overview - Aptose is committed to developing precision medicines to address unmet medical needs in oncology, with a focus on hematology [5] - The company's pipeline includes small molecule cancer therapeutics designed for single-agent efficacy and to enhance the efficacy of other anti-cancer therapies without overlapping toxicities [5] - Tuspetinib (TUS) is an oral kinase inhibitor that has shown activity as both a monotherapy and in combination therapy for patients with relapsed or refractory AML, and is being developed as a triplet therapy for newly diagnosed AML [5] Conference Details - The 2025 Bloom Burton & Co. Healthcare Investor Conference will feature corporate updates from various Canadian healthcare companies, providing opportunities for investors to engage with company representatives [4] - Dr. William G. Rice's corporate presentation is scheduled for May 5, 2025, at 3:00 p.m. EDT, and will be available via webcast [3]

Core Viewpoint - Aptose Biosciences Inc. has been determined by the Nasdaq Hearings Panel to delist its common shares from Nasdaq due to non-compliance with the Exchange's equity requirement by the deadline of March 31, 2025 [1] Company Overview - Aptose Biosciences is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [3] - The company's lead compound, tuspetinib (TUS), is an oral kinase inhibitor aimed at treating acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy for newly diagnosed AML patients [3] Delisting Details - The Nasdaq Hearings Panel's decision was based on Aptose's failure to demonstrate compliance with the equity requirement outlined in Listing Rule 5550(b)(1) by the specified date [1] - Trading of Aptose's common shares will be suspended effective April 2, 2025, following the Panel's determination [1] Future Plans - The company and its board are considering all available options, including an appeal against the delisting decision, while continuing to execute its business plan [2] - Aptose intends to seek a listing on a U.S. national Securities Exchange at an appropriate time [2]